The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Oral Erythromycin and the Risk of Sudden Death from Cardiac Causes
Open accessAbstract
BACKGROUND: Oral erythromycin prolongs cardiac repolarization and is associated with case reports of torsades de pointes. Because erythromycin is extensively metabolized by cytochrome P-450 3A (CYP3A) isozymes, commonly used medications that inhibit the effects of CYP3A may increase plasma erythromycin concentrations, thereby increasing the risk of ventricular arrhythmias and sudden death. We studied the association between the use of erythromycin and the risk of sudden death from cardiac causes and whether this risk was increased with the concurrent use of strong inhibitors of CYP3A. METHODS: We studied a previously identified Tennessee Medicaid cohort that included 1,249,943 person-years of follow-up and 1476 cases of confirmed sudden death from cardiac causes. The CYP3A inhibitors used in the study were nitroimidazole antifungal agents, diltiazem, verapamil, and troleandomycin; each doubles, at least, the area under the time-concentration curve for a CYP3A substrate. Amoxicillin, an antimicrobial agent with similar indications but which does not prolong cardiac repolarization, and former use of erythromycin also were studied, to assess possible confounding by indication. RESULTS: The multivariate adjusted rate of sudden death from cardiac causes among patients currently using erythromycin was twice as high (incidence-rate ratio, 2.01; 95 percent confidence interval, 1.08 to 3.75; P=0.03) as that among those who had not used any of the study antibiotic medications. There was no significant increase in the risk of sudden death among former users of erythromycin (incidence-rate ratio, 0.89; 95 percent confidence interval, 0.72 to 1.09; P=0.26) or among those who were currently using amoxicillin (incidence-rate ratio, 1.18; 95 percent confidence interval, 0.59 to 2.36; P=0.65). The adjusted rate of sudden death from cardiac causes was five times as high (incidence-rate ratio, 5.35; 95 percent confidence interval, 1.72 to 16.64; P=0.004) among those who concurrently used CYP3A inhibitors and erythromycin as that among those who had used neither CYP3A inhibitors nor any of the study antibiotic medications. In contrast, there was no increase in the risk of sudden death among those who concurrently used amoxicillin and CYP3A inhibitors or those currently using any of the study antibiotic medications who had formerly used CYP3A inhibitors. CONCLUSIONS: The concurrent use of erythromycin and strong inhibitors of CYP3A should be avoided.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
J Heart Lung Transplant 2021;40(4).
(2021) · The Journal of Heart and Lung Transplantation · doi:10.1016/j.healun.2021.04.002 · Cited by 6,665
Fish Consumption and Risk of Sudden Cardiac Death
Albert, C. M. (1998) · JAMA · doi:10.1001/jama.279.1.23 · Cited by 990
The accuracy of Medicare's hospital claims data: progress has been made, but problems remain.
Fisher, E. S., Whaley, F. S., Krushat, W. M., Malenka, D. J., Fleming, C., Baron, J. A., & Hsia, D. C. (1992) · American Journal of Public Health · doi:10.2105/ajph.82.2.243 · Cited by 709
Torsades de Pointes Occurring in Association With Terfenadine Use
Monahan, B. P. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450210088038 · Cited by 667
Clinical classification of cardiac deaths.
Hinkle, L. E., & Thaler, H. T. (1982) · Circulation · doi:10.1161/01.cir.65.3.457 · Cited by 638
Diuretic Therapy for Hypertension and the Risk of Primary Cardiac Arrest
Siscovick, D. S., Raghunathan, T. E., Psaty, B. M., Koepsell, T. D., Wicklund, K. G., Lin, X., Cobb, L., Rautaharju, P. M., Copass, M. K., & Wagner, E. H. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406303302603 · Cited by 434
Antipsychotics and the Risk of Sudden Cardiac Death
Ray, W. A., Meredith, S., Thapa, P. B., Meador, K. G., Hall, K., & Murray, K. T. (2001) · Archives of General Psychiatry · doi:10.1001/archpsyc.58.12.1161 · Cited by 429
Self-citationOlkkola, K. T., Backman, J. T., & Neuvonen, P. J. (1994) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1994.60 · Cited by 409
Recall Accuracy for Prescription Medications: Self-report Compared with Database Information
West, S. L., Savitz, D. A., Koch, G., Strom, B. L., Guess, H. A., & Hartzema, A. (1995) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a117563 · Cited by 352
USE OF MEDICAID DATA FOR PHARMACOEPIDEMIOLOGY
RAY, W. A., & GRIFFIN, M. R. (1989) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115198 · Cited by 315
Self-citationCyclic antidepressants and the risk of sudden cardiac death
Ray, W. A., Meredith, S., Thapa, P. B., Hall, K., & Murray, K. T. (2004) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2003.09.019 · Cited by 274
Self-citationQT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience
De Ponti, F., Poluzzi, E., & Montanaro, N. (2000) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050714 · Cited by 240
Wiseman, L. R., & Faulds, D. (1994) · Drugs · doi:10.2165/00003495-199447010-00008 · Cited by 238
Cardiac Actions of Erythromycin: Influence of Female Sex
Drici, M.-D., Knollmann, B. C., Wang, W.-X., & Woosley, R. L. (1998) · JAMA · doi:10.1001/jama.280.20.1774 · Cited by 194
Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients
Curtis, L. H., Østbye, T., Sendersky, V., Hutchison, S., Allen LaPointe, N. M., Al-Khatib, S. M., Usdin Yasuda, S., Dans, P. E., Wright, A., Califf, R. M., et al. (2003) · The American Journal of Medicine · doi:10.1016/s0002-9343(02)01455-9 · Cited by 176
Shaffer, D., Singer, S., Korvick, J. A., & Honig, P. K. (2002) · Clinical Infectious Diseases · doi:10.1086/340861 · Cited by 151
Prescription of QT-prolonging drugs in a cohort of about 5 million outpatients
Curtis, L. H., Østbye, T., & Sendersky, V. (2003) · ACC Current Journal Review · doi:10.1016/s1062-1458(03)00200-9 · Cited by 149
Comparing Sources of Drug Data about the Elderly
Johnson, R. E., & Vollmer, W. M. (1991) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1991.tb02872.x · Cited by 148
Plasma buspirone concentrations are greatly increased by erythromycin and itraconazole*
Kivistö, K. T., Lamberg, T. S., Kantola, T., & Neuvonen, P. J. (1997) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(97)90038-2 · Cited by 147
USE OF AUTOMATED DATABASES FOR PHARMACOEPIDEMIOLOGY RESEARCH
Strom, B. L., & Carson, J. L. (1990) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036064 · Cited by 138
Marcus, G. M., Cobb, L. A., Edwards, J. E., Kuller, L. H., Moss, A. J., Bigger, J. T., Fleiss, J. L., Rolnitzky, L. M., & Serokman, R. (1988) · The American Journal of Cardiology · doi:10.1016/0002-9149(88)91295-7 · Cited by 132
Rawson, N. S. B., & Malcolm, E. (1995) · Statistics in Medicine · doi:10.1002/sim.4780142404 · Cited by 130
Gil, M. M. P., Sala, M., Anguera, I., Chapinal, O., Cervantes, M., Gumà, J. R., & Segura, F. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00906-8 · Cited by 113
Verapamil intoxication: A literature review of overdoses and discussion of therapeutic options
Hofer, C. A., Smith, J. K., & Tenholder, M. F. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90314-f · Cited by 100
Stanat, S. J. C., Carlton, C. G., Crumb, W., Agrawal, K. C., & Clarkson, C. W. (2003) · Molecular and Cellular Biochemistry · doi:10.1023/a:1027309703313 · Cited by 91
Ahonen, J., Olkkola, K. T., & Neuvonen, P. J. (1997) · European Journal of Clinical Pharmacology · doi:10.1007/s002280050223 · Cited by 85
Validation of Two Methods of Data Collection of Self-Reported Medicine Use Among the Elderly
Landry, J. A., Smyer, M. A., Tubman, J. G., Lago, D., Roberts, J. R., & Simonson, W. (1988) · The Gerontologist · doi:10.1093/geront/28.5.672 · Cited by 81
Damkier, P., Hansen, L. L., & Brøsen, K. (1999) · British Journal of Clinical Pharmacology · doi:10.1046/j.1365-2125.1999.00099.x · Cited by 79
Identification and Characterization of Human Cytochrome P450 Isoforms Interacting with Pimozide
Desta, Z., Kerbusch, T., Soukhova, N. V., Richard, E., Ko, J.-W., & Flockhart, D. A. (1998) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)37449-x · Cited by 75
METHODOLOGICAL ISSUES IN EVALUATING EXPANDED MEDICAID COVERAGE FOR PREGNANT WOMEN
Piper, J. M., Ray, W. A., Griffin, M. R., Fought, R. L., DAUGHTERY, J. R., & Mitchel, E. F. (1990) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115692 · Cited by 72
Self-citationPharmacokinetic interaction between ritonavir and clarithromycin*
Ouellet, D., Hsu, A., Granneman, G. R., et al. (1998) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(98)90065-0 · Cited by 70
Shigeki Matsumoto, & Yamazoe, Y. (2001) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2001.01292.x · Cited by 70
Abernethy, D. R. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.114230 · Cited by 63
Varis, T., Backman, J. T., Kivistö, K. T., et al. (2000) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2000.104611 · Cited by 49
Warot, D., Bergougnan, L., Lamiable, D., et al. (1987) · European Journal of Clinical Pharmacology · doi:10.1007/bf00543975 · Cited by 47
Amiodarone-cyclosporine interaction in a heart transplant patient.
Nicolau, D. P., Uber, W., Crumbley, A. J., & Strange, C. (1992) · PubMed · Cited by 44
A Comparison of Patient Drug Regimens as Viewed by the Physician, Pharmacist and Patient
Leister, K. A., Edwards, W. A. (., Christensen, D. B., & Clark, H. (1981) · Medical Care · doi:10.1097/00005650-198106000-00008 · Cited by 44
Tschida, S. J., Guay, D. R. P., Straka, R. J., Hoey, L. L., Johanning, R. J., & Vance‐Bryan, K. (1996) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1996.tb03650.x · Cited by 43
Compound Cardiac Toxicity of Oral Erythromycin and Verapamil
Goldschmidt, N., Azaz‐Livshits, T., Gotsman, I., Nir‐Paz, R., Ben‐Yehuda, A., & Muszkat, M. (2001) · Annals of Pharmacotherapy · Cited by 35
Cisapride-Cimetidine Interaction
Kirch, W., Janisch, H. D., Ohnhaus, E. E., et al. (1989) · Therapeutic Drug Monitoring · doi:10.1097/00007691-198907000-00007 · Cited by 33
Long Q-T Syndrome Associated with Oral Erythromycin Used in Preoperative Bowel Preparation
Vogt, A. W., & Zollo, R. A. (1997) · Anesthesia & Analgesia · doi:10.1213/00000539-199711000-00010 · Cited by 21
Cited by
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Intensive Care Medicine · doi:10.1007/s00134-017-4683-6 · Cited by 6,621
Priori, S. G., Blomström-Lundqvist, C., Mazzanti, A., Blom, N., Borggrefe, M., Camm, J., Elliott, P. M., Fitzsimons, D., Hatala, R., Hindricks, G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv316 · Cited by 3,893
Surviving Sepsis Campaign: International guidelines for management of sepsis and septic shock: 2016.
Rhodes, A., Evans, L. E., Alhazzani, W., Levy, M. M., Antonelli, M., Ferrer, R., Kumar, A., Sevransky, J. E., Sprung, C. L., Nunnally, M. E., et al. (2017) · Critical Care Medicine · doi:10.1097/ccm.0000000000002255 · Cited by 3,652
Zipes, D. P., Camm, A. J., Borggrefe, M., Buxton, A. E., Chaitman, B., Fromer, M., Gregoratos, G., Klein, G., Myerburg, R. J., Quinones, M. A., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.010 · Cited by 1,973
Kleinman, M. E., Chameides, L., Schexnayder, S. M., Samson, R. A., Hazinski, M. F., Atkins, D. L., Berg, M. D., de Caen, A. R., Fink, E. L., Freid, E. B., et al. (2010) · Circulation · doi:10.1161/circulationaha.110.971101 · Cited by 1,949
Metadata
- Authors
- Ray, W. A., Murray, K. T., Meredith, S., Narasimhulu, S. S., Hall, K., & Stein, C. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-09-09
- Volume
- 351
- Issue
- 11
- Pages
- 1089-1096
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2616625093
- Cited by
- 496
- References
- 41
- FWCI
- 23.13
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.